Light Chain Usage in Anti-double-stranded DNA B Cell Subsets: Role in Cell Fate Determination

By Linda Spatz,*Vladimir Saenko,[‡] Andrey Iliev,[‡] Lori Jones,[‡] Larisa Geskin,[‡] and Betty Diamond^{*‡}

From the *Department of Medicine, and [‡]Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461

Summary

Two major mechanisms for the regulation of autoreactive B cells that arise in the bone marrow are functional silencing (anergy) and deletion. Studies to date suggest that low avidity interactions between B cells and autoantigen lead to B cell silencing, whereas high avidity interactions lead to deletion. Anti–double stranded (ds) DNA antibodies represent a pathogenic autospecificity in Systemic Lupus Erythematosus (SLE). An understanding of their regulation is critical to an understanding of SLE. We now demonstrate in a transgenic model in which mice express the heavy chain of a potentially pathogenic anti-DNA antibody that antibody affinity for ds-DNA does not alone determine the fate of anti-dsDNA B cells. B cells making antibodies with similar affinities for dsDNA are regulated differently, depending on light chain usage. A major implication of this observation is that dsDNA may not be the self antigen responsible for cell fate determinations of anti-dsDNA B cells. Light chain usage may determine antigenic cross-reactivity, and cross-reactive antigens may regulate B cells that also bind dsDNA.

A nti-double stranded (ds)¹ DNA antibodies are characteristic of the autoimmune disease SLE and titers of IgG anti-dsDNA antibodies in patients' serum correlate with disease activity and nephritis. Analyses of the immunoglobulin variable region gene loci reveal no differences between autoimmune and nonautoimmune mouse strains and no differences in human kindreds that associate with autoimmune disease. Furthermore, the immunoglobulin variable region (V) genes used in both murine and human anti-DNA antibodies are also used in the generation of a protective antibody repertoire (1–5).

Studies of the regulation of autoreactive B cells became possible with the advent of transgenic technology. Analyses of B cells expressing transgene encoded autoantibodies have demonstrated the existence of several mechanisms for maintaining self tolerance: functional silencing or anergy, deletion, and receptor editing (6–13). Based on investigations from several laboratories, Goodnow has proposed that there are thresholds of receptor occupancy that correlate with different mechanisms of regulation (14). According to this model, deletion occurs under conditions of extensive receptor cross-linking, whereas silencing occurs under conditions of more moderate cross-linking.

To study the regulation of anti-dsDNA antibodies, we previously generated nonautoimmune BALB/c and NZW

mice transgenic for the γ 2b heavy chain of the R4A antidsDNA antibody. The R4A antibody is encoded by an S107 V11 heavy chain gene and a Vk1 light chain gene, binds dsDNA, and deposits in glomeruli of SCID mice (15, 16). In R4A- γ 2b transgenic BALB/c and NZW mice, negligible anti-DNA activity is present in the serum, and fusion of unstimulated splenocytes from these mice fails to yield transgene expressing anti-dsDNA hybridomas. Anti-dsDNA B cells, however, are present in the spleens of these mice and can be activated in vitro by LPS to secrete transgene encoded anti-dsDNA antibody. Furthermore, R4A anti-dsDNA hybridomas can be obtained from these mice if splenocytes are stimulated in vitro with LPS before fusion (9, 17).

In the present study we compared transgene expression in nonautoimmune BALB/c and NZW mice and autoimmune NZB/W F1 mice. While negligible transgene-encoded anti-DNA activity is present in the serum of BALB/c and NZW mice, such activity is present in the serum of all NZB/W F1 mice. Analyses of hybridomas show that transgene expressing anti-dsDNA B cells from NZB/W F1 mice use a broad spectrum of light chain genes. In contrast, anti-dsDNA B cells from nonautoimmune mice use almost exclusively Vk1 genes. Thus, two populations of antidsDNA B cells exist, which are differentially regulated in nonautoimmune mice. There is a Vk1 anti-dsDNA subset that is present but is functionally silent, and a non-Vk1 subset which is targeted for deletion. In the NZB/W F1 autoimmune background, both populations are activated in vivo. Since the Vk1 and the non-Vk1 anti-dsDNA anti-

1317

¹Abbreviations used in this paper: ds, double-stranded; FR1, framework 1; ss, single-stranded; V, variable region.

bodies have similar affinities for dsDNA, this critical, potentially pathogenic, specificity cannot be regulated solely by binding to dsDNA. Alternative models of regulation in which cell fate is determined by light chain usage need to be considered.

Materials and Methods

Transgenic Mice. Mice expressing the R4A- γ 2b heavy chain transgene have been previously reported (9, 17). Transgene expressing NZB/W F1 mice were generated by breeding transgenic NZW mice with wild-type NZB mice.

Generation of Hybridomas. Spleens cells derived from two 8-wkold unimmunized transgenic NZW mice and two unimmunized transgenic BALB/c mice were fused after stimulation for 48 h in vitro with LPS (17).

Six fusions were performed using spleen cells from eight NZB/W F1 transgenic mice ranging in age from 2.5–10 mo. Three fusions were performed with naive spleen cells; two were performed with LPS stimulated cells. In one fusion, half of the splenocytes were stimulated with LPS for 48 h before fusion and the other half were fused without prior exposure to LPS. Hybridomas were screened by ELISA for γ 2b dsDNA binding as previously described (17). Cells from hybridoma wells displaying anti-dsDNA activity were cloned in soft agar.

Analysis of V Gene Expression. Hybridoma clones were screened for expression of R4A- γ 2b and Vk1 genes by RNA dot blot using probes specific for the mouse S107 and Vk1 gene families as previously described (17). A Vk1 probe was provided by Dr. C. Schildkraut (Albert Einstein College of Medicine, Bronx, New York; reference 18).

Total RNA was isolated from hybridomas (Ultraspec RNA kit; Biotecx Labs., Houston, TX). First strand cDNA for the R4A heavy chain and κ light chain genes were synthesized using 10 μ g of RNA and 100 ng of antisense oligonucleotide primers specific for the mouse gamma constant region (TGGACAGGGA/CTC-CAG/TAGTTC) and for the mouse k light chain constant region (ACACTCATTCCTGTTGAA). PCR amplification was performed using vent polymerase. For the R4A heavy chain gene, an oligomer specific for framework 1 (FR1; GGTGAAGCTG-GTGGAATCTGG) and the gamma constant region primer were used; for kappa light chain genes a Vk1, FR1-specific oligomer (CCAGCAGTGATGTTGTGATGACCC) or a cocktail of degenerate FR1, Vk oligomers (19), and the κ constant region primer were used. PCR products were sequenced with the ds-DNA cycle sequencing system (GIBCO BRL, Gaithersburg, MD) using constant region, FR1, and internal primers. Sequencing reactions were electrophoresed on 6 or 7% acrylamide gels.

Allelic Exclusion. Allelic exclusion of anti-dsDNA hybridomas was determined by ELISA as previously described (17). In brief, 96-well Falcon plates (Becton Dickinson, Lincoln Park, NJ) were coated with a 1/1,000 dilution of goat anti-mouse antibody to IgM, IgG1, IgG3, IgG2a, or IgG2b (Southern Biotechnology Assoc., Birmingham, AL). After blocking plates in PBS, 1.0% BSA, cell supernatants normalized to 10 μ g/ml were added to wells for 1 h at 37°C followed by the addition of goat anti-mouse IgM, IgG1, IgG3, IgG2a, or IgG2b antibody, respectively, conjugated to alkaline phosphatase (Southern Biotechnology Assoc.). All ELISA washes were performed with PBS–0.05% Tween. ELISAs were developed with *p*-nitrophenylphosphate disodium as substrate (Sigma Chemical Co., St. Louis, MO) and ELISAs were read at 405 nm in a Titertek-Multiscan ELISA reader.

Antibody Quantitation. IgG2b antibodies in hybridoma supernatants were quantitated by ELISA as previously described (16).

Analysis of Antigenic Specificity. Quantitated hybridoma supernatants were tested by ELISA for binding to dsDNA and single stranded (ss) DNA. The dsDNA ELISA was performed on salmon sperm DNA-coated Immulon 2 ELISA plates (Dynatech Labs. Inc., Chantilly, VA) according to Iliev et al. (17). The ss-DNA ELISA was performed as described for dsDNA (17) except that salmon sperm DNA was not filtered through a nitrocellulose filter and was denatured by boiling and quick cooled on ice before coating Immulon 2 plates.

Affinity Measurements of Anti-dsDNA Antibodies. Affinity constants for selected anti-dsDNA antibodies were determined according to an antigen inhibition ELISA as described by Nieto et al. (20). Immulon 2 plates were coated with 100 µg/ml salmon sperm DNA and blocked in PBS, 1.0% BSA. Hybridoma supernatants diluted to an antibody concentration that was within the linear range on an anti-dsDNA antibody titration curve, were then incubated in wells of ELISA plates along with increasing concentrations of soluble salmon sperm DNA used as inhibitor (0.0-2 mg/ml) for 2 h at 37°C. Wells were washed and incubated for 1 h at 37°C with goat anti-mouse IgG2b conjugated to alkaline phosphatase and developed with substrate solution as described above. ELISA measurements were read at 405 nm in a Titertek Multiscan ELISA reader. Apparent affinities were calculated based on the concentration of soluble DNA resulting in 50% inhibition of antibody binding (20).

Dissociation constants were determined according to the method of Friguet et al. (21). In brief, linearized plasmid DNA was nick translated with ³²P-labeled deoxynucleotide triphosphates. A constant amount of antibody was combined with various amounts of radiolabeled DNA (5–100 ng), brought to a final volume of 1.0 ml with SSC, and then incubated for 3 h at room temperature. Antibody–dsDNA complexes were trapped on 0.45 μ m type HA millipore filters (Millipore Corp., Bedford, MA). Bound radioactivity was detected on a liquid scintillation counter. Results were plotted and dissociation constants were obtained from the slope of the linear regression.

Pathogenicity of Anti-dsDNA Antibodies. Hybridoma cells (5 \times 10⁶) from two lines, BW7E6H1 and NZW14E10, were injected intraperitoneally into pristane-primed SCID mice. 3 wk after injections, animals were killed, and kidneys removed and imbedded in paraffin. Sections were stained with biotin-conjugated goat anti-mouse IgG (Vectastain ABC kit; Vector Labs., Inc., Burlingame, CA) and then developed with NBT-BCIP substrate (GIBCO BRL) according to Katz et al. (16). Stained sections were viewed with a Zeiss microscope.

Results

Generation of Hybridomas from Nonautoimmune Mice. While splenocytes from nonautoimmune NZW and BALB/c R4A- γ 2b transgenic mice can be induced to secrete transgene encoded anti-dsDNA antibodies by in vitro stimulation with LPS, spontaneous secretion of γ 2b antidsDNA antibody is negligible in these mice (9). In contrast, NZB/W F1 R4A- γ 2b transgenic mice have elevated titers of γ 2b anti-dsDNA. These antibodies are transgene encoded; at 2.5–3 mo of age, elevated titers of γ 2b DNA binding activity is present only in the sera of transgenic NZB/W F1 mice and not in nontransgenic littermates (Fig. 1).

To understand the differential regulation of anti-dsDNA



Figure 1. Measurement of R4A- γ 2b anti-dsDNA antibody in the sera of NZB/W F1 transgenic and non transgenic mice. Sera from 10 transgenic (*Tg*+) NZB/W F1 mice and 10 nontransgenic (*Tg*-) littermates were diluted 1/500 and then tested by ELISA for binding of γ 2b antibody to dsDNA. Ages of Tg+ and Tg- mice range from 10–21 wk. There is no linear relationship between age of the mouse and anti-dsDNA titer within these populations. *Mean value significantly exceeds mean value for Tg- mice. *P* <0.002 (Student's *t* test).

B cells in autoimmune and nonautoimmune mice, we generated transgene encoded anti-dsDNA hybridomas. We were able to obtain anti-dsDNA producing hybridomas from NZW or BALB/c mice only if splenocytes were cultured with LPS before fusion (17). 5–10% of hybridomas from LPS-stimulated splenocytes expressing the R4A- γ 2b transgene bound dsDNA. 20 anti-dsDNA hybridomas, 9 from NZW mice, and 11 from BALB/c mice, were analyzed in detail. Expression of the transgene was verified in these clones by sequencing through the VDJ junction of the γ 2b heavy chain in all hybridomas and throughout the entire V region in half. Sequence analysis revealed the heavy chain to be encoded by the transgene in all cases and further revealed that there was no somatic mutation of the R4A heavy chain.

To examine the endogenous light chains expressed in these hybridomas, we first looked for expression of a Vk1 transcript by RNA dot blot since the "wild-type" R4A antibody possesses a Vk1 light chain (15). 17 of 20 lines expressed a Vk1 light chain. All light chains were sequenced (Fig. 2) confirming the light chain identification obtained by RNA dot blot. The Vk1-A gene was used in the majority (12) of hybridomas. 16 of the Vk1 light chain genes were somatically mutated. The three non-Vk1 anti-dsDNA associated light chains, BA12BB2, BA12BD-1, and BA1227, were derived from BALB/c hybridomas and are encoded by Vk21, Vk2, and Vk4/5 genes respectively (data not shown).

Generation of Hybridomas from NZB/W F1 Autoimmune Mice. Transgene expressing anti-dsDNA hybridomas from R4A-y2b transgenic NZB/W F1 mice could be obtained from non-LPS activated B cells as well as from LPS activated splenocytes, confirming activation in vivo of antidsDNA B cells in the autoimmune mice. In contrast to the dominant Vk1 usage seen in nonautoimmune mice, only 5 of 16 autoimmune derived anti-dsDNA hybridomas use a Vk1 gene (Table 1). 12 cell lines were obtained from LPSstimulated splenocytes, of which only 4 (33%) use Vk1 genes. Only 1 of 4 cell lines obtained from unstimulated NZB/W F1 splenocytes (25%) uses a Vk1 light chain. Therefore, there is little difference in the frequency of Vk1 expression in hybridomas from LPS-stimulated and unstimulated splenocytes. Vk1 genes from NZB/W F1 hybridomas display no somatic mutation in three (BW19G10, BW21D11, and BW10D9) of the five Vk1 genes sequenced (Fig. 3). The base change observed at the junction of Vk and Jk in Bw19G10 and BW21D11 is likely the result of imprecise joining during Vk-Jk rearrangement.

The remaining 11 hybridomas use light chains from eight different non-Vk1 light chain gene families (Fig. 4), including two from the Vk10 family and three from the Vk4/5 family. Since none of the non-Vk1 genes share 100% homology with any germline genes reported in the EMBL/GenBank/DDBJ database, we cannot determine whether they are somatically mutated or whether they represent novel germline genes.

We previously observed that R4A anti-dsDNA hybridomas from nonautoimmune mice display a lack of allelic exclusion, whereas the transgene expressing non-dsDNA binding hybridomas all display intact allelic exclusion (17). We, therefore, examined the R4A anti-dsDNA hybridomas from NZB/W F1 mice for expression of endogenous μ , γ 1, γ 3, or γ 2a heavy chain. Hybridoma supernatants were assayed by ELISA for binding to anti-isotype antibodies. Most hybridomas (14 of 16) were observed to express endogenous heavy chain as well as the R4A- γ 2b heavy chain. In nine hybridomas, the endogenous heavy chain is of the μ isotype; in 5, it is of the γ 3 or γ 2a isotype. All hybridomas failing to display allelic exclusion demonstrated expression of a second isotype as detected by an OD reading that was at least fivefold above background levels (OD405 nm >0.6). Two hybridomas from NZB/W F1 mice, BW10D9 and BW7E6, demonstrated no binding above background to anti- μ , $\gamma 1$, $\gamma 3$, or $\gamma 2a$ (OD_{405 nm} <0.150) suggesting that they maintained allelic exclusion or that they secreted an endogenous γ 2b heavy chain.

Comparison of Vk1 and Non-Vk1 Anti-DNA Antibodies. Comparison of the light chain repertoire of transgeneencoded anti-dsDNA antibodies used by the nonautoimmune and autoimmune mice (Table 1) demonstrates a statistically significant dominance of Vk1 light chains in hybridomas from the nonautoimmune BALB/c and NZW mice. To understand how R4A-Vk1 anti-DNA antibodies might differ from R4A non-Vk1 anti-DNA antibodies, we compared

Δ	CDR1
Vk1-A	D V V M T Q T P L S L P V S L G D Q A S I S C <u>R S S O S L V</u> GATGTTGTGATGACCCAAACTCCACTCTCCCGCCTGTCAGTCTTGGAGATCTAGCCCACAGTCAGGCCTGTA
BA12CB-1	нС
BA141AX2	н С
DALGER G	н
BAI2DE-2	Н
BA149A-2	
BA129B-1	CATC
NZW5G3	L
NZW10D8	c
NZW12F7	
NZW4B9	
NZW11F7	E G
NZW8E4	I L T
NZW2C8	
1011200	
	CDR2
	<u>HSNGNTYLH</u> WYLQXPGQSPKLLIY <u>KVSNRJ</u>
Vk1-A	CACAGTRACUGAAACACCTATTTACATTGGTRCCTGCRGAAGCCRGGCCRG
BA12CB-1	
BA141AX2	
BA126E-2	
BA149A-2	
BA129B-1	
NZW5G3	M TG
NZW1008	
NZW12F7	
N2544H9	
NENTIFI	
NZW814	G
NZW2C8	
Vkl-A	S G V P D R F S G S G S G T D F T L K I S R V E A E D L G V TCT0966TCCCA6ACAG6TCCAGTG6CAGTG6GACCA66GATCAC6GACCACACTCAA6ACTCAA6AGCTG6CGAC6ACCTG6CGAC
BA12CB-1	
84°413X2	
241267 2	
ыя149А-2	3
BA1298-1	gg
NZW5G3	с
NZW1CD8	-G
NZW12F7	
NZW439	к С
NZW11F7	L A
NZW8E4	5 AG
N702/28	A C
144200	ч ч
	2002
	CDR3 YFCSOSTHVP

	YFCS <u>QSTHVP</u>													
Vk1~A	TATTTCTGCTCTCAAAGTACACATGTTCCG						Jr	egi	on					
	S	W	Т	F	G	G	G	т	Κ	L	Е	Ι	K	
BA12CB-1	gT-C	TGG	ACG	TTC	GGT	GGA	GGC.	ACC	AAG	CTG	GAA	ATC.	AAA	$J_{k}1$
		W	т	F	G	G	G	т	К	L	Е	I	К	
BA141AX2		TGG	ACG	TTC	GGT	GGA	GGC.	ACC	AAG	CTG	GAA	ATC.	AAA	$J_k 1$
		L	т	F	G	А	G	т	Κ	L	Е	L	K	
BA126E-2		CTC	ACG	TTC	GGT	GCT	GGG.	ACC.	AAG	CTG	GAG	CTG	ААА	J _x 5
		Y	т	F	G	G	G	Τ	R	L	Е	I	ĸ	
BA149A-2		TAC	ACG	TTC	GGA	GGG	GGG	ACC.	AGG	CTG	GAA	ATA	AAA	J _k 2
		R	т	F	G	G	G	T	к	Ľ	E	Ι	К	
BA129B-1	t	CGG	ACG	TTC	GGI	GGA	GGC	ACC.	AAG	CTG	GAA	ATC	AAA	J _k 1
		R	т	F	G	G	G	т	К	L	E	Ι	К	
NZW5G3		CGG	ACG	TTC	GGI	GGA	GGC	ACC.	AAG	CTG	GAA	ATC	AAA	$J_k 1$
		F	т	F	G	S	G	т	K	L	Е	Ι	к	
NZW10D8	a	TTC	ACG	TTC	GGC	TCG	GGG.	ACA.	AAG	TTG	GAA	ATA	AAA	J _k 4
		Y	T	F	G	G	G	т	. K	L	E	1	ĸ	
NZW12F7	t	TAC	ACG	TTC	GGA	GGG	GGG.	ACC.	AAG	CTG	GAA	ATA	AAA	J _x 2
	G	Y	т	F	G	G	G	т	К.	L	E	1	ĸ	- 0
NZW4B9	GG	TAC	ACG	TTC	GGA	GGG	GGG.	ACC.	AAG	CTG	GAA	A'I'A	AAA	J _x 2
		R	T	F	G	G	G	T	. K	L	E	1	к.	
NZWIIF/		CGG	ACG	TTC	CGI	GGA	GGC	ACC.	AAG	CTG	GAA	ATC	AAA	0 kT
10000 64		T T	T	5 770	G	G	God	T	Х.	ь 0750	ь 			T 0
NZW814		TAC	ACG	TTC	GGR	000	666	m m	AAG	-10	GAA	ATA T	NMA V	υ _k Ζ
NIGNOOD		ChC	1	E.	G		600	T.	л 200		с. С. Л. Л.	يد مسم	7 7	T D
N4WZC8	C	CAC	ACG	110		000	000	ncc.	mn0	C10	GAA	ATA	nnn	∪k∠

binding to dsDNA by ELISA (Fig. 5). A similar spectrum of binding was present among antibodies with both Vk1 and non-Vk1 light chains. Several non-Vk1 antibodies displayed lower dsDNA binding than Vk1 antibodies, demonstrating that the non-Vk1 antibodies did not represent a

В	DVVVTOTPLSLPY	ISFGDO	. V S T S C	CDR1
36.1.2D	GATGTTGTGGTGACTCAAACTCCACTCTCCCTGCCTG	CAGCT'I'IGGAGATCA	AGTTTCTATCTCTTGC	AGGTCTAGTCAGAGTCTTGCA
NZW14E10				
BA12CD-1	G	cc		
	<u>NSYGNTYLS</u> WYL	I K P G Q S	PQLLI	CDR2 Y <u>G I S K R F</u>
36.1.2D	AACAGTTATGGGAACACCTATTTGTCTTGGTACCTGC/	CAAGCCTGGCCAGTC	TCCACAGCTCCTCATCI	ATGGGATTTCCAAGAGATTT N
N2W14E10	S		н	С N L Т
BA12CD-1	C		C	CCTGACC
36 1 20	S G V P D R F S G S G S C	T D F T L	K I Š T I	K P E D L G M
NZW14E1.0				
NEWIGEIO	E T		RV	ea v
BAISCD-1	àcàà		gaG-G-GC	;GEG-'I'
36.1.2D	Y Y C <u>L O S T H O P</u> TAPTACTGCTTACAAAGTACACATCAGCCG	J regio	n	
NZW14E10	G L T G	F G A G T	X L E L K	J.5
B&12CD=1		F G G G T	K L E I K	-x-
Databet 1				~ 24
~				0081
C	DVLMTQTPLST, PV	л ѕ г с р д	ASISC	<u>RSSOSIV</u>
VRI-C	GATOPPPTGATGACCCAAACTCCACTCTCCCTGCCTC	rCAUTCTTGGAGATCA	AGECTECATETECI	GATCTAGTCAGAGCATTGTA
NZW6B11				
BA145D-2	λ			
BA1224-2	C			
	HSNGNTYLENVI) K P G O S	. р. к. т. т.	CDR2
Vk1-C	CATAGTAATGGAAACACCTATTTAGAATGGTACCTCC	GAAACCAGGCCAGTC	TCCAAAGCTCCTGATCT	ACAAAGTTTCCAACCGATTT
NZW6B11				
3A145D-2				
BA1224-2	I P C	·?	c	G G
Vk1-C	S G V P D R F S G S G S C TCTGGGGTCCCAGACAGGTCCAGTGGCAGTGGATCAGG	GACACATTCACACT	K I S R V CARGATCAGCAGAGING	S A S D L G V
N2%6B11				
1014512-3	2			
DALIGD-2	L I L			
BA1224-2	CIG			
	CDP3			
	YYC <u>FQGSHV</u> P			
Vk1-C	TATTACTGCTTTCAAGGTTCACATGTTCC	T	J region	TETE
NZW6B11		- GTCACGTTCG	GCTCGGGGGACAAAG	TTGGAAATAAAA J _x 4
DN145D	2	Y T F C	G G G T K	LEIK
BAI45D-1	۷ مت	W T F (G G G T K	LEIK
BA1224-	2	g TGGACGTTCG	GTGGAGGCACCAAG	CTGGAAATCAAA J _k 1

Figure 2. Nucleotide and amino acid sequences of Vk1 light chains from nonautoimmune transgenic hybridomas. Light chain nucleotide and amino acid sequences from hybridomas from nonautoimmune BALB/c and NZW transgenic mice are compared to their most homologous Vk1 germline genes. (A) Vk1-A; (B) 36.1.2D, an atypical Vk1- α (1–6) dextran germline gene; and (C) Vk1-C (38-40). CDR regions are underlined and are according to Kabat et al. (40). Dashes indicate identity of nucleotides to the germline sequence. Silent base changes are designated by lowercase letters. Nucleotide changes leading to amino acid replacements in the V region are indicated by uppercase letters. Those leading to amino acid replacements in the joining (J) regions are indicated in bold uppercase letters. Amino acid replacements are shown above the nucleotide sequence. Amino acid replacements from the germline J are indicated in bold. Light chains derived from BALB/c mice have the prefix BA preceding the numeric designation. Light chains derived from NZW mice have the prefix NZW preceding the numeric designation.

higher affinity subset. We also measured the apparent affinity of some representative Vk1 and non-Vk1 anti-dsDNA antibodies in a DNA inhibition assay (20). There was no difference in the range of affinities among the Vk1 and the non-Vk1 anti-dsDNA antibodies (Table 2). One antibody

Table 1.Vk Gene Usage

Total No.	Vk1 (%)	Non-Vk1 (%)
11	8 (73)	3 (27)
9	9 (100)	0 (0)
16	5 (31)*	11 (69)
12	4 (33)	8 (66)
4	1 (25)	3 (75)
	Total No. 11 9 16 12 4	Total No. Vk1 (%) 11 8 (73) 9 9 (100) 16 5 (31)* 12 4 (33) 4 1 (25)

*Significantly less than NZW (P < 0.002) and BALB/c (P < 0.05) Pearson χ^2 test.

which binds only moderately well to dsDNA-coated plates (BW16B2) by direct ELISA, appears to have a higher apparent affinity, as detected by a DNA inhibition ELISA, than expected. This antibody may bind better to DNA in solution than to DNA in a solid phase, a characteristic of some anti-DNA antibodies which has previously been observed (22).

Because it has been reported that B cells with specificity for ssDNA are tolerized by anergy induction, while B cells binding dsDNA are deleted (8), we assayed for cross-reactivity with ssDNA by ELISA (Table 3). At 2 µg/ml, one Vk1 anti-dsDNA antibody, BA129B-1, derived from a BALB/c mouse, and two non-Vk1 anti-dsDNA antibodies, BW14C7B1 and BW9B5F7, derived from an NZB/W F1 mouse bind strongly to ssDNA (Table 3) relative to R4A. Two other anti-dsDNA antibodies, one from a BALB/c mouse and one from an NZB/W F1 mouse, show less than a twofold increase in binding ssDNA relative to R4A. The remainder



of the anti-dsDNA antibodies from both autoimmune and nonautoimmune mice display binding to ssDNA less than twofold greater than the binding of R4A.

To test for pathogenicity, a Vk1-expressing cell line, NZW145-D2, derived from an NZW transgenic mouse, and a non-Vk1 expressing line, BW7E6H1, derived from an NZB/W F1 transgenic mouse, were injected into SCID mice. NZW145D-2 and BW7E6H1 were selected for pathogenicity studies because both cell lines are allelically excluded and secrete only the transgenic antibody. Furthermore, antibodies from both hybridomas have similar binding characteristics. They both bind moderately well to ds-DNA by ELISA (Fig. 5) and both have dissociation constants in the range of 10^{-9} - 10^{-8} as detected by a filter binding assay (21). After 3 wk, kidneys were removed from these mice and stained for antibody deposition. In both cases, deposition of IgG was observed in glomeruli (Fig. 6, B and C) suggesting that both Vk1 and non-Vk1 R4A anti-dsDNA antibodies have pathogenic potential.

Discussion

Anti-dsDNA antibodies represent a major pathogenic specificity in SLE. To understand their regulation in nonautoimmune and autoimmune hosts, we generated mice expressing the heavy chain of an IgG2b pathogenic antidsDNA antibody. This heavy chain, expressed in association with an endogenous light chain repertoire, can form antibodies with a variety of affinities for dsDNA. The analysis of serum and hybridomas from R4A transgenic mice leads to several important observations.

The first observation is that there is a defect in tolerance



Figure 3. Nucleotide and amino acid sequences of Vk1 light chains from autoimmune transgenic hybridomas. Light chain nucleotide and amino acid sequences from hybridomas from autoimmune NZB/W F1 transgenic mice are compared to their most homologous Vk1 germline genes. (*A*) Vk1-A, (*B*) Vk1-B, and (*C*) Vk1-C (38, 41). CDR regions are underlined and are according to Kabat et al. (40). Dashes indicate identity of nucleotides to the germline sequence. Silent base changes are designated by lowercase letters. Nucleotide changes leading to amino acid replacements in the V region are indicated by uppercase letters. Those leading to

amino acid replacements in the J regions are indicated in bold. Amino acid replacements are indicated above the nucleotide sequence. Amino acid replacements from the germline J are indicated in bold. The BW prefix precedes all numeric designations of light chains derived from NZB/W F1 mice.

	D V V M T Q ? P L T L S L T I G Q P À S I S C <u>K S S O S L L</u>
VK2 BW98597	GATGITUTGATGACTCAGACCCCACTCACCTTGTGCCCTACCATTGGACAACCAGCCTCCATCCCCTGCAAATCAAGTCAGACCAGCCTCTTA
VK24 DW1818	GAIWITIGIGATGACGCAGGCTGCATTCTCCAATCCAGTCACTCTEGAACACCAGCTTCCATCTCTTECAGTTCTAGTAAGAGTCTCCTA
Vk21 BW12F3	GATGITGIGATGACICAGGCIGCACCCTCTOTACCTGTCACTCCTGGAAAGAGTCTACGTATGACAGTCTCCTG
VK9 BWGB9F9	D I E M T Q S P S S L S A S L G E R I S L T C <u>R A S O D .</u> GACATIGAGAIGACCCAGTETECTECTETETEGEGAGAAAGAATEAGTETEACTIGEEGGGGCAAGTEAGGAEATT
VK10 BW16B2	D V Q M T Q S P S S L S A S L G D T I T I T C <u>R A S O N I</u> BACOTCOAGATOACCOAGTOTOCOAGTOTOCOCOCOGAGACACATTACCATCACTGCOAGTOAGAACATT
DW7F5	D V Q M T Q T T S S L S A S L C D R V T I S C <u>R A S O D I</u> GACGICCAGAIGACCCAGACTACATECTECCECTETECEGEGAGACAGAGTEACCATEACTECEGEGAGACAAGTCAGGACATT
1000 D Dive T	DIVMTQSPATLSVTPGDSVTPGDSSSSSSSSSSSSSSSSSSSSSSSSSSS
VK23 DHOT	I V M I Q S Q K F M S T S V C D R V S I T C <u>K A S O V</u>
VK19 BW/18601	G I V L S Q S ? G I M S A S P G E K V T M T C <u>S A S S S T</u>
VK4/5 BW10C2	GAATIGTETETECCAGTETECEAGGATEATGTETEGEATETECEAGGGAGAAGGTEACCATGACETGEAGTGECAGETEAAGFATA G I V L T Q S P A I M S A S P G E K V T M S C <u>S A S S S V</u>
BW14C7B1	GRAFTGITCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAAGGTCACCATGTCCTGCAGGTCAAGCAGTGCAGGTCAGGTCAGGTCAGCAGGCAG
BW15D5F2	GGAATTUTTCTCACCCAUTCCCAGCAATCATGTCTSCATCTCCABGSGAGAAGGTCACCATGACCTBCAGTGCCASCTCAAGTSTA
	CDK2 <u>ESNGKTYI</u> NWILQRPGQSPKPLIY <u>LVS</u> KLE
VK2 B%9B5	CATAGTAATGGAAAGACATATTTGAATTGGTTATTACAGAGGCCGAGTCTCCAAAGCCCCTAAYCTATCTGGTGTCTAAACTGGAA
VK24 HW18FS	CATAGTAATGGCATCACTTATTTGCATTCUCTATCTGCAGAGACCAGGCCAGTCTCCTCAGGCTCUTGATATAATGGGATGCCCAACCTTGCC
VK21 BW12F3	CATAGTAATGGCAACACTTACTTOTATTGGTTCCTGCAGAGGCCAGGCC
VK9 BWGB9F9	<u>X G S. L X</u> W F Q Q K P D G T 1 K L L I Y <u>G T S S L D</u>
VK10 EW16B2	N L W L S W Y Q Q K P G N I P K L L I Y <u>K A S N L H</u>
340ME	<u>SNYLNWYOQKPJGATCAGCAGAAACCAGATGATCATTAACTCCHARTTACTCCHARTTACTCCAGCAGAAACCAGATGATCATTAACTCCHARTT</u>
10023 0016211	<u>S_NNLH</u> WYQQKSKESSKESSKESSKESSKESSKESSKESSKESSKESS
VK23 BW5711	<u>R T A V A</u> W Y Q Q K P G Q S P K A L I Y <u>L A S N R H</u>
VK19 BW726	STATES A CONTRACTOR ACCASES AND A CONSISTENCES AND A CONTRACTOR ACCESSED AND ACCES
VK4/5 BW10C2	
BW14C7B1	
BW15D6F2	AGTTACATGTACTGGTACCAGCAGAAGCCAGGATCCTCCCCCAGACTCCTGATTTATGACACATCCAACCTGGCT
1000 DM055	S G V P D R F S C S G S G D F I. K I S K V E A E D L G V
VK2 88955	S G V P D R F S C S G S G C D F C I. K I S K V E A E D L G V TOTGAGOCCTGACAGETICAGTOGCASCULATICAGCOGCAGATITICACCTGAGAATCOGOCCTGAGAATCOGOGYT S G V P D R F S G S G S G T D 7 T I. R S R V E A E D V G V
VK2 88955 VK24 881858	S G V P D R F S G S G S G C D P C I, K I S K V E A E D L G V TOTGGAGCCCTGACNGOTLOGGGCATUURUCGGACATTACCTGACATTACACTGACAATAGCAGAGAGAG
VR2 BW955 VR24 BW18F8 VR21 BW1273	S G V P D R F S G S G S G C D P C I. K I S K V E A E D L G V TOTGRACHTCHOTGOCATURITICADORACHTUTTACHTCHANTCHAURANTURGADATTIGADATTIGGUNGT S G V P D R F S G S G S G T D P T I. R $-$ S R V L A \ge D V G V TORGADATTICATINGCATURITICADORACTIANTICACHTURANTURGADATTIGGUNGT X G V P D R F S G S G S G Y A F T I. R I S R V L A \ge D V G V TIMADASTICCADALADORACHTURITICATURICALUMATICADATTICAL STANDARTICADATTIGGUNGT TIMADASTICCADALADORACHTURITICALUMATICADATTICAL STANDARTICADATTICADATTICADATTICADATTICADATTICADATICADATT
VK2 BM955 VK24 BM18F8 VK21 BM12F3 VK2 BM12F3	S G V P D R F S C S G S G C D F C I. K I S K V E A E D L G V CYGGAROCCTORONOGTICAGTORICACTURICACIONALITICACITEMANTCACAMUTICACIONTICACIONALITICICCONTINUCICALINALITICICCONTINUCICALINALITICICCONTINUCICALINALITICICCONTINUCICALINALITICICCONTINUCICALINALITICICCONTINUCICALINALITICICCONTINUCICALINALITICICCONTINUCICALINALINALITICICCONTINUCICALINALINALINALINALINALINALINALINALINALIN
VK2 BX955 VK24 BW18F8 VK21 BW12F3 VK2 BW3F9 VK9 BW3B9F9 VK10 BW16B2	S G V P D R F S C S C S C C D F C L K I S K V E A E D L G V CYTGRAGATOCTANONGTURATION OF A CLASSICAL CONTRACTOR AN ALCONAUTOCIDAD TURAN TO GRADY S G V P D R F S C S C S G T D 7 L R S R V L A 2 D V G V TO SOMATICCARACAGTICATION CASTURIZMOMA CTAINTECACTOR ACCURATE CURACITICATION CONTRACTOR S G V P D R F S C S C S G A F L I R I S R V L A 2 D G V THANGAMTICCARACAGTICATION CASTURIZMOMA CTCATTECACTOR ACTIVITIES AND ALCONTRACTOR TO CONTRACTOR TO CONTRACT AND ALCONTRACT AND ALCONTRAC
VK2 BM955 VK24 BM18F8 VK21 BM18F8 VK2 BM089F9 VK10 BM16B2 EW75	S G V P D R F S C S C S C C D F C L K I S K V B A E D L G V COTORACIÓN CONTRACTOR CONCACULARIZACIÓN MAITTACA TRAVATCIANA INCLACIÓN MUDICIÓN DE MAIS S C V P D R F S C S C S G T D F C L F S S V E A 2 D V S V TOSONATICO DALASOTICIÓN CAUTURICACIÓN ACTUAITON ACTUAL COMPLICIÓN ACTUAL CONTRACTIÓN ACTUAL S C V P D R F S C S C S G A F C L P I S L V A V S V G V TRADAMITICO DALASOTICIÓN CAUTURICACIÓN ACTUAL TO NA COMPLICIÓN ACTUAL COMPLICIÓN ACTUAL CONTRACTIÓN ACTUAL CONTRACTÓN ACTUAL CONTRACTÓN ACTUAL CONTRACTÍNA DE VILLO DE V S C V P D R F S C S C S G V A F C L I S S L V A L D F A D TUTION TUTOL COMPLICATION CONTRACTOR TONON ACTUAL TO NA CONTRACTÍNA DE VILLO DE
VK2 BM955 VK24 BM1858 VK21 BM1858 VK21 BM1858 VK9 BM08969 VK10 BM1682 BM775 BM6511	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
VK2 B&955 VK24 BW19F8 VK21 BW12F3 VK9 BW089F9 VK16B2 BW16B2 E6V7F5 BW6F11 VK23 BW7F5	S G V P D R F S G S G S G C D F C L K I S K V E A E D L G V CONSTRUCTOR CONTACT AND CONSTRUCTOR CONTACT AND CONSTRUCTOR CONTACT AND CONSTRUCT
VX2 NX955 VX24 NH989 VX24 NH989 VX2 NH0899 VX10 NH182 VX24 NH182 VX25 NH182 VX26 NH611 VX26 NH621 VX26 NH782 VX45 NH192	S G V P D R F S G S G S G C D P C L K I S K V B A E D L G V CONSTRUCTOR CONTACT AND CONSTRUCTOR CONTACT AND CONSTRUCT AND CONST
VX2 NX355 VX24 N/1352 VX21 NX125 VX10 NX1622 VX23 NK6511 VX45 BH052 VX45 BH102 NX45 BH102	S G V P D R F S G S G S G S G C D F C L K I S K V B A E D L G V TOTGGACTCOTTACTGGACATURATICADGACATURATICADGACATURATICACTAGUAAUCUAAUCUAAUCUAAUCUAAUCUAAUTUAGUAAUCUAAUTUAGUAAUCUAAUC
VK2 N0995 VK24 N01873 VK24 N01273 VK25 N0162 PW75 N1621 VK23 N16521 VK45 BU1027 BU1427N1 H0150522	S G V P D R F S C S G S G 7 D F 7 I. K I S K V E A E D L G V TYTERGARCCETARAATTCARGUEAUUURACUURACUURACUURACUURACUURACUURACU
VK2 Hx949 VK24 Hx14873 VK21 Aw1273 VK24 Aw1273 VK10 Bw1621 VK2 Bw1621 VK4 Bw1022 VK4 Bw10275	S G V P D R F S C S G S G 7 D P 7 I. K I S K V E A R D L G V TOTGGACCECTACAGUELAGUEAGUEAGUEAGUEAGUEAGUEAGUEAGUEAGUEAGUE
VK2 H04955 VK24 H041987 VK21 H04127 VK2 H0457 VK10 H04562 H04757 H0457 VK24 H04757 VK45 H04277 VK45 H04262 H045762 H04262	S G V P D B F F S G S G S G T D F T L K I S K V B A B D L G V P S G V P D F F S G S G S G T D F T L K I S K V B A B D L G V P S C S G S G T D F T L K I S K V B A B D L G V C V C V C V C V C V C V C V C V C V
VX.2 H0495 VX.24 H0498 VX.1 H0498 VX.1 B0499 VX.10 B0475 VX.23 B06711 VX.45 B041022 B042771 H04952	S G V P D R F S G S G S G T D F T L K I S K V E A E D L G V TOTGAGOCCETACADUTACIONCOLATUURICACIONAMITTACATENALAMATICACIONALTUGADOTTAGANTYOGONOTT S G V P D R F S G S G S G S G T D P T L R S R V E A 2 D V G V TOTGAGONETICATIVECTICATUURICACIONALITICACTICACTUMANTCACIONALITIC
VK2 HN955 VK2 HN958 VK1 ant2x3 VK1 BN0599 VK10 BN75 VK23 BN6711 VK14 BN102 BN14C7B1 BN105052 VK2 RN955	S G V P D R F S G S G S G S G T D F T L K I S K V E A E D L G V TOTGAGACCETTACAGOGACATURACCOCACATURACCOCACATUTACATCACACATURACATUCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACACATURACATURACCACATURACATURACCACATURACATURACATURACTURAC
VK2 N0095 VK24 N01873 VK24 N01623 VK10 N01623 VK13 N06511 VK14 N01023 N14477 N01023 N144778 N01023	S G V P D R F S G S G S G C D P C L K I S K V B A E D L G V TOTGAGACCOTTACTOGCATURATICACTORACATURATICAC TO ALMANICA CARACTALIAGAT TO GRAPT S G V P D R F S G S G S G C D P T L K I S K V E A B D V G V TOTGAGATCOTTACTOGCATURATICACTURACIONAL CARACTALITICACTORACINATICACIONAL TO GRAPT X G V P D R F S G S G S G C T D P T L F I S K V E A B D V G V THAGAMACTICATICACTURACIONAL CARACTACTICACTORACTALIANAL CARACTALITICACIONAL CARACTALIANAL C
VK2 N00957 VK24 N01873 VK21 N01273 VK21 N01621 VK3 N01621 VK3 N06211 VK4 N0162 VK3 N0162 VK4 N01858 VK4 N01858	S G V P D R F S C S C S C S C T D P T L K I S K V E A R D L G V T T T T T T T T T T T T T T T T T T
VK2 INU957 VK24 INU197 VK1 INU197 VK1 INU175 VK2 INU175 VK2 INU75 VK2 INU75 VK2 INU15057	S G V P D R F S C S G S G T D P T L K I S K V E A R D L G V TOTGGACCETACAGTICAGGACATUCAGGACAGAATTACCCCCACAGAACAGAATGAGACAGAATGAGACAGAATGAGACAGAATGAGACAGAATGAGACAGAATGAGAGACAGAATGAGAGAGA
VX2 INU BES VX24 INU BES VX21 INU BES VX2 INU BES VX2 INU BES VX4 INU BES VX44 INU BES VX45 INU BES	S G V P D R F S G S G S G T D F T L K I S K V E A E D L G V TOTGAGACCETACAGTICAGTOGCATUURCACCACATUTICACTECALATACACCACATUCCACATUTCACCACATURCACCACATURCACCACAUCACAU
VX2 N0955 VX24 N01982 VX1 N01982 VX1 N01982 NX1 N01982 VX1 N075 VX23 N076 VX44 N01982 VX45 N01982 VX45 N01982 VX45 N01982 VX45 N01982 VX45 N01982 VX46 N01982 VX47 N01982 VX48 N01982 VX49 N01982 VX49 N01982 VX49 N01982 VX49 N01982 VX19 N01982 VX19 N01982	S G V P D R F S G S G S G T D F T L K I S K V E A E D L G V TOTGAGACCETACAGUTACTUCAGUCACUACUCACUACUCACUACUTACUCACUACUCACUACUCACUACUCACUACUCACUACUCACUACU
VX.2 INUBSC VX.4 INUBSC VX.4 INUBSC VX.4 INUSC VX.4 INUSC	S G V P D R F S C S G S G T D F T L K I S K V E A E D L G V TOTGAGACCETACAGOTICATION OF A CONTRACTOR AND TACACTAGA AND A CONTRACTAGAT TACGOTICATION AND TAGANATION AND TACTAGAT AND TACACTAGAT AND TACA
VX.2 N0.955 VX.2 N0.1573 VX.1 N0.1573 VX.1 N0.1573 VX.2 N0.6711 VX.4 N0.1576 VX.5 N0.1577	S G V P D R F S C S G S G 7 D P 7 L K I S K V E A E D L G V TETGGACCETTACTORTOGOCATUARCOCASULARCOCASULATITACTOCACCAMATICACAMATICACCAMATICACCAMATICACCAMATICACCAMATICACCAMATI
VK2 INUBSP VK21 INUBSP VK21 INUSPS VK23 INUSPS VK24 INUSPS VK2 INUSPS VK2 INUSPS VK4 INUSPS	S G V P D R F S C S C S G T D P T L K I S K V E A R D L G V TOTGAGCCETACAGTICAGGGCATUURCAGGAACUTACAGGAACAATTACCCCCACAAAACAAATCAGAACTAGAACTAGAACTAGGGAATTACCCCC S G V P D R F S G S G S G S G T D P T L F S R V E A 2 D V G V TAGGGATCCAAACAACTAGCTAGGGCATUURCAGGAACTATTACACTAAAATCAAACAAATCAGAACTA
VK2 INUE VK24 INUE VK20 INUE VK10 INUE INUE INUE VK20 INUE VK10 INUE VK20 INUE VK14 INUE VK14 INUE VK14 INUE VK14 INUE VK21 INUE VK22 INUE VK23 INUE VK14 INUE VK23 INUE VK34 INUE VK34 INUE VK34 INUE INUE INUE VK34 INUE INUE INUE	S G V P D R F S G S G S G T D P T L K I S K V E A E D L G V TOTGAGACCETARADATICAGUGATUURGGAATUURGGAAATITTAAATTAAAATAAAAATGAGUAAATTAGUGAATTAAATTAAA S G V P D R F S G S G S G S G T D P T L F I S R V E A E D V G V TAGGAGUCCAAAAAATTAGUGAGUGAUUAGGAATUURGGAATAATTAAATTA
VX.2 IN49573 VX.1 IN419573 VX.1 IN419573 VX.1 IN41973 IN47 IN4797 VX.1 IN4797 VX.1 IN4797 VX.3 IN4797 VX.4 IN4797 VX.4 IN41027 VX.4 IN41027 VX.2 IN41273 VX.2 IN41283 VX.2 IN41283 VX.2 IN41283 VX.2 IN41283 VX.3 IN41283 VX.4 IN41283 VX.3 IN41283 VX.3 IN47953 VX.3 IN47953 VX.3 IN47953 VX.3 IN47953 VX.3 IN47953 VX.3 IN47953	S G V P D R F S C S C S G T D F T L K I S K V E A E D L G V TOTGAGACCETACAGOTACIGGOCATUURCACCACAATTITICA CTEMAATCACACAATCACCACAATTACACAATTACCACAATTACCACAATTACACAATTACCACAATTACACAATTACACAATTACACAATTACCAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTACAATTA
VX.2 N.393 VX.4 N.193 VX.4 N.039 VX.1 N.039 VX.1 N.193 VX.2 N.193 VX.4 N.193	S G V P D R F S G S G S G T D F T L K I S K V E A E D L G V TOTGAGCCETACAGOTACTUGUEGOCATUURCOGACATUTTCACTEGALATACAGAGCAGAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA

0071

Figure 4. Nucleotide and amino acid sequences of non-Vk1 light chains from autoimmune transgenic hybridomas. Light chain nucleotide and amino acid sequences from hybridomas from the autoimmune NZB/W F1 transgenic mice are grouped according to families. Family assignment is based on having >90% homology with other family members as reported in EMBL/GenBank/DDBJ. CDR regions are underlined and are according to Kabat et al. (40). Dots have been introduced in CDR1 to maximize homology. Nucleotide changes leading to amino acid replacements in the J regions are indicated in bold uppercase letters. Amino acids are designated by uppercase letters. Replacements from the germline J region are in bold. *N*, represents a nucleotide that could not be resolved by sequencing.

induction in transgenic NZB/W F1 mice leading to elevated serum titers of transgenic γ 2b anti-dsDNA antibody in this autoimmune strain. In the autoimmune MRL/lpr mouse which has a defect in the Fas gene, Roark et al. have similarly observed a breakdown of tolerance of transgenic anti-dsDNA antibodies (23) and have suggested that loss of Fas may lead to the accumulation of autoreactive B cells. Other studies, however, have demonstrated intact regulation of transgenic autoantibodies in MRL/lpr mice suggesting that Fas is not essential for maintaining B cell tolerance (24, 25). Studies in transgenic NZB/W F1 mice may help us determine what factors, besides decreased Fas expression, may lead to a breakdown in tolerance in autoimmune-prone mice.

A second observation is that the transgenic anti-dsDNA antibodies derived from NZB/W F1 mice are often encoded by unmutated light chain genes. 3 out of 5 Vk1 genes are unmutated in NZB/W F1 mice compared to 1 out of 17 in BALB/c and NZW mice. Although studies of anti-dsDNA antibodies from nontransgenic NZB/W F1 mice show the antibody genes to be somatically mutated, little information is available on whether the mutations lead to specificity for dsDNA or whether the autoreactivity is germline encoded. It is possible that autoreactive B cells whose specificities are germline encoded escape regulation in the bone marrow and exit to the periphery where they then acquire somatic mutations after activation by self antigens. Thus, there are two possible explanations for the fact that autoantibodies obtained from nontransgenic NZB/W F1 mice are somatically mutated; either the mutations are necessary for autospecificity, or the mutations occur in already autoreactive B cells that are not tolerized. Our studies indicate that in the transgenic NZB/W F1 mice, antidsDNA B cells arising in the bone marrow can move into peripheral lymphoid organs and secrete germline encoded autoantibody. Furthermore, B cell activation occurs without molecular evidence for T cell help.

A third observation from our studies is that transgene expressing anti-dsDNA hybridomas from both nonautoimmune and autoimmune strains display a lack of allelic exclusion. In NZW- and BALB/c-derived hybridomas, the majority of endogenous antibodies display no binding to dsDNA. We had previously speculated that the endogenous heavy chain is instrumental to survival of the autoreactive B cell (17). In the NZB/W F1-derived hybridomas, however, the endogenous heavy chain may display DNAbinding specificity (Spatz, L., V. Saenko, and B. Diamond, unpublished observations). Therefore, the reason for the lack of allelic exclusion in transgenic NZB/W F1 mice is unclear. Although many anti-dsDNA B cells present in nontransgenic NZB/W F1 mice have been shown to display intact allelic exclusion, the frequency of nonallelically excluded autoreactive B cells has not been examined in these mice. It has been demonstrated in B cells of MRLlpr/lpr mice transgenic for an anti-DNA antibody, that allelic exclusion is more often absent than in B cells from nonautoimmune transgenic strains (26). Perhaps there is an intrinsic B cell defect in both MRL/lpr and NZB/W F1 B cells such that the production of a transgenic heavy chain does not effectively repress further heavy chain rearrangements.

A fourth and major observation is that anti-dsDNA antibodies from the nonautoimmune mice preferentially use Vk1 light chains, whereas those obtained from autoimmune mice



Figure 5. Binding to dsDNA. Hybridoma supernatants from (BA), NZW, and BALB/c NZB/W F1 (BW) transgenic mice were normalized to a $\gamma 2b$ concentration of 10 µg/ml and assayed for binding to salmon sperm dsDNA by ELISA. Wildtype R4A-y2b antibody and irrelevant γ 2b are used as positive and negative controls, respectively. Shaded boxes, Vk1 antibodies; open boxes, non-Vk1 antibodies. (A) Strong dsDNAbinding antibodies. Strong ds-DNA binders are defined as those whose ELISA measurements at 405 nm are at least fourfold greater than R4A after a 4-h incubation with alkaline phosphatase substrate solution. (B) Moderate dsDNA-binding antibodies. Moderate dsDNA binders are defined as those whose ELISA measurements at 405 nm range from 0.75-2-fold that of R4A after overnight incubation with substrate solution. Results are the average of triplicates \pm standard deviation. Standard deviations <0.010 do not appear on the bar graph.

are encoded by a broad spectrum of Vk genes. This finding suggests that autoreactive B cells expressing non-Vk1 light chains are deleted from the nonautoimmune strains and that light chain usage influences cell fate. Further support for the deletion of non–Vk1-R4A B cells in nonautoimmune mice comes from studies of BALB/c mice transgenic for both R4A- γ 2b and bcl-2. These mice have transgenic anti-DNA B cells in the spleen expressing a broad spectrum of Vk genes (Kuo, P., and B. Diamond, unpublished observations).

Decreased Vk1 usage in NZB/W F1 mice is not due to

1323 Spatz et al.

an abnormality in the κ light chain gene locus of the NZB mouse. Autoantibody production has been observed in many different Igk-V haplotypes and RFLP analysis has failed to identify particular lupus-associated Igk-V genes (27). Previous studies suggest that the Igk-V gene loci in autoimmune mouse strains are normal (28) and Gavalchin et al. have demonstrated that the V regions encoding a set of pathogenic anti-DNA antibodies in the (NZB \times SWR)F1 lupus-prone mice are often derived from the nonautoimmune SWR parental strain (1). Allelic polymorphisms exist among individual light chain genes from different inbred

 Table 2.
 Affinity Measurements of Anti-dsDNA Antibodies

Cell line	Affinity constants	Vk family		
	aKa*			
B12CB-1	$6.60 imes10^8$	Vk1		
BA129B-1	$1.10 imes10^9$	Vk1		
NZW5G3	$1.1 imes 10^{9}$	Vk1		
NZW14E10	$1.65 imes10^9$	Vk1		
NZW2C8	$1.32 imes10^9$	Vk1		
BW10D9	$5.08 imes10^8$	Vk1		
BW7F5	$1.76 imes10^9$	Vk10		
BW16B2	$6.60 imes10^8$	Vk10		
BW14C7B1	$1.32 imes10^9$	Vk4/5		
BW9B5F7	$5.29 imes10^9$	Vk2		

*Apparent affinity constants (aKa) measured by inhibition ELISA according to Nieto et al. (20). Data shown are representative of a minimum of two assays done in triplicate.

strains. However, this cannot account for the dominant usage of Vk1-A light chains among anti-dsDNA antibodies obtained from transgenic BALB/c mice and their relative paucity among transgenic anti-dsDNA antibodies obtained from NZB/W F1 mice because an identical Vk1-A gene is present in both strains (29). Furthermore, it is unlikely that the dominant expression of Vk1 genes by anti-dsDNA antibodies obtained from the nonautoimmune transgenic mice is due to biased use of Vk1 genes in cells expressing the R4A- γ 2b transgene. None of the 19 randomly selected R4A-y2b-expressing, non–DNA-binding antibodies from NZW hybridomas express a Vk1 light chain (17). The predominant expression of Vk1 anti-dsDNA antibodies, therefore, demonstrates that anti-DNA B cells with non-Vk1 light chains are targeted for deletion in nonautoimmune strains.

To understand why Vk1-expressing B cells escape to the periphery and persist in an unactivated, silent state, whereas non-Vk1 B cells undergo deletion in nonautoimmune strains, we looked for differences in binding to dsDNA that might

Table 3. Cross-reactivity with ssDNA

Cell lines	OD 405 nm
BA129B-1	2.468 ± 0.203
BA126E-2	0.303 ± 0.051
BW14C7B1	2.768 ± 0.119
BW9B5F7	2.202 ± 0.101
BW15D6F2	0.286 ± 0.044
R4A	0.159 ± 0.013

ELISA measurements of anti-dsDNA antibodies that cross-react with ssDNA. Results are the average of triplicates \pm standard deviation.

account for their differential regulation. While current models of B cell tolerance suggest that low avidity interactions with antigen lead to anergy while high avidity interactions lead to deletion, Vk1 and non-Vk1 anti-dsDNA antibodies demonstrate similar affinities for dsDNA. The difference in regulation, therefore, does not appear to be due to a difference in affinity for dsDNA. Nor does the difference in regulation correlate with differences in the pathogenic potential of these antibodies. Cell lines secreting a Vk1 and non-Vk1 anti-dsDNA antibody were injected into SCID mice and both antibodies deposited in glomeruli.

The relative contribution of kappa light chains in DNA specificity have previously been reported (30, 31). Radic et al. have demonstrated that the pairing of the 3H9 anti-DNA heavy chain with different light chains alters the ability of the antibody to bind dsDNA, cardiolipin, and RNA, although all antibodies retain the ability to bind ssDNA (31). More recently, Retter et al. has suggested that the light chain may confer upon the antibody a second cross-reactive specificity (32). We propose that perhaps it is on the basis of a second light chain-associated specificity that B cells producing R4A anti-dsDNA antibodies are either deleted or silenced. To begin to test this hypothesis, we measured binding of hybridoma antibodies to ssDNA. Although we have identified a few antibodies that bind strongly to ssDNA, we have not observed any trend that might explain the differential regulation of Vk1 and non-Vk1 antibodies. In fact, two of these antibodies use non-Vk1 genes and appear to be deleted from the nonautoimmune mice rather than anergized as one might expect.

The simplest interpretation of our studies is that DNA is not the critical antigen mediating selection of these autoreactive B cells. There is increasing evidence that anti-DNA antibodies can cross-react with several other self antigens including fibronectin, laminin, heparan sulfate, collagen, and cardiolipin, as well as nuclear antigens (33–37). If dsDNA were the critical selecting antigen and receptor occupancy alone determined cell fate, then both Vk1 and non-Vk1 B cells would undergo the same form of negative selection. Just as recent data raise the possibility that anti-DNA antibodies may mediate tissue injury by binding cross-reactive antigens, anti-DNA B cells may be regulated by cross-reactive antigens.

This transgenic model provides a unique opportunity to study the molecular basis for differential regulation of autoreactive B cells, and suggests that affinity for dsDNA is not the critical determinant of the fate of anti-dsDNA B cells. If dsDNA is indeed a self antigen capable of mediating negative selection, our data suggest that antigen binding on the membrane of a B cell may engage the B cell receptor complex to either delete or inactivate autoreactive B cells depending on properties not correlated with affinity for antigen. More likely, different light chains associating with the R4A heavy chain mediate binding to cross-reactive antigens and this cross-reactivity plays a role in determining the fate of the autoreactive anti-dsDNA B cells. The identity of these putative cross-reactive antigens remains to be determined in future studies. A B C

Figure 6. Glomerular deposition of Vk1 and non-Vk1 antidsDNA antibodies. SCID mice were injected with 5×10^6 hybridoma cells secreting (A) a control non-DNA-binding IgG antibody, (B) aVk1 anti-dsDNA antibody, NZW145D-2, and (C) a non-Vk1 anti-dsDNA antibody, BW 7E6H1. Kidney sections were stained with goat anti-mouse IgG conjugated to alkaline phosphatase and viewed on a Zeiss microscope. ×100. No deposition is observed in mice receiving the cell line producing the non-DNA binding antibody. Glomerular deposits are observed in B and C.

We would like to thank Amy Gilkes for her assistance. We would also like to express our sincere gratitude to Dr. Barbara Birshtein, Dr. Barry Bloom, and Dr. Matthew Scharff for their critical reading of this manuscript.

This project is supported by National Institutes of Health grants AI40163 (L. Spatz) and AR42533 (B. Diamond) and grants from the New York Chapter of the Arthritis Foundation. Linda Spatz is a recipient of a Young Scholar Award granted by the New York Partnership in Arthritis Research of the Arthritis Foundation, New York Chapter.

Address correspondence to Linda Spatz, Albert Einstein College of Medicine, Microbiology and Immunology, Forchheimer 405, Bronx, NY 10461.

Received for publication 30 September 1996 and in revised form 24 January 1997.

References

- Gavalchin, J., J.A. Nicklas, J.W. Eastcott, M.P. Madaio, B.D. Stollar, R.S. Schwartz, and S.K. Datta. 1995. Lupus prone (SWR × NZB) F1 mice produce potentially nephritogenic autoantibodies inherited from the normal SWR parent. *J. Immunol.* 134:885–894.
- 2. Datta, S.K., B.D. Stollar, and R.S. Schwartz. 1983. Normal mice express idiotypes related to autoantibody idiotypes from lupus mice. *Proc. Natl. Acad. Sci. USA*. 80:2723–2727.
- Krishnan, M.R., and T.N. Marion. 1993. Structural similarity of antibody variable regions from immune and autoimmune anti-DNA antibodies. *J. Immunol.* 150:4948–4957.
- Kofler, R., D.J. Noonan, D.E. Levy, M.C. Wilson, N.A. Moller, F.J. Dixon, and A.N. Theofilopoulos. 1985. Genetic elements used for a murine lupus anti-DNA autoantibody are closely related to those for antibodies to exogenous antigens. *J. Exp. Med.* 161:805–815.
- Manheimer-Lory, A., R. Monhian, A. Splaver, B. Gaynor, and B. Diamond. 1995. Analysis of the Vk1 family: germline genes from an SLE patient and expressed autoantibodies. *Autoimmunity*. 20:259–265.
- Goodnow, C.C., J. Crosbie, S. Adelstein, T.B. Lavoie, S.J. Smith-Gill, R.A. Brink, H. Pritchard-Briscoe, J.S. Wotherspoon, R.H. Loblay, K. Raphael et al. 1988. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. *Nature (Lond.).* 334:

676-682.

- Nemazee, D.A., and K. Burki. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. *Nature (Lond.)*. 337:562–566.
- Erikson, J., M.Z. Radic, S.A. Camper, R.R. Hardy, C. Carmack, and M. Weigert. 1991. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. *Nature* (*Lond.*). 349:331–334.
- Offen, D., L. Spatz, H. Escowitz, S. Factor, and B. Diamond. 1992. Induction of tolerance to an IgG autoantibody. *Proc. Natl. Acad. Sci. USA*. 89:8332–8336.
- Okamoto, M., M. Murakami, A. Shimizu, S. Ozaki, T. Tsubata, S. Kumagai, and T. Honjo. 1992. A transgenic model of autoimmune hemolytic anemia. *J. Exp. Med.* 175: 71–79.
- 11. Tiegs, S.L., D.M. Russell, and D. Nemazee. 1993. Receptor editing in self-reactive bone marrow B cells. *J. Exp. Med.* 177:1009–1021.
- Gay, D., T. Saunders, S. Camper, and M. Weigert. 1993. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177:999–1008.
- Tsao, B.P., A. Chow, H. Cheroutre, Y.W. Song, M.E. McGrath, and M. Kronenberg. 1993. B cells are anergic in transgenic mice that express IgM anti-DNA antibodies. *Eur. J. Immunol.* 23:2332–2339.

- 14. Goodnow, C.C. 1992. Transgenic mice and analysis of B-cell tolerance. *Annu. Rev. Immunol.* 10:489–518.
- Shefner, R., G. Kleiner, A. Turken, L. Papazian, and B. Diamond. 1991. A novel class of anti-DNA antibodies identified in BALB/c mice. *J. Exp. Med.* 173:287–296.
- Katz, J.B., W. Limpanasithikul, and B. Diamond. 1994. Mutational analysis of an autoantibody: differential binding and pathogenicity. J. Exp. Med. 180:925–932.
- Iliev, A., L. Spatz, S. Ray, and B. Diamond. 1994. Lack of allelic exclusion permits autoreactive B cells to escape deletion. *J. Immunol.* 153:3551–3556.
- Moynet, D., S.J. MacLean, K.H. Ng, D. Anctil, and D.M. Gibson. 1985. Polymorphism of k variable region (Vk-1) genes in inbred mice: relationship to the Igk-Ef2 serum light chain marker. *J. Immunol.* 134:3455–3460.
- Kettleborough, C.A., J. Saldanha, K.H. Ansell, and M.M. Bendig. 1993. Optimization of primers for cloning libraries of mouse immunoglobulin genes using the polymerase chain reaction. *Eur. J. Immunol.* 23:206–211.
- Nieto, A., A. Gaya, M. Jansa, C. Moreno, and J. Vives. 1984. Direct measurement of antibody affinity distribution by hapten-inhibition enzyme immunoassay. *Mol. Immunol.* 21: 537–543.
- Friguet, B., A.F. Chaffotte, L. Djavadi-Ohaniance, and M.E. Goldberg. 1985. Measurement of the true affinity constant in solution of antigen–antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods. 77:305–319.
- Pisetsky, D.S., and C.F. Reich. 1994. The influence of DNA size on the binding of anti-DNA antibodies in the solid and fluid phase. *Clin. Immunol. Immunopathol.* 72:350–356.
- Roark, J.H., C.L. Kuntz, K.-A. Nguyen, A.J. Caton, and J. Erikson. 1995. Breakdown of B cell tolerance in a mouse model of systemic lupus erythematosus. J. Exp. Med. 181:1157– 1167.
- 24. Rathmell, J.C., and C.C. Goodnow. 1994. Effects of the lpr mutation on elimination and inactivation of self-reactive B cells. J. Immunol. 153:2831–2842.
- Rubio, C.F., J. Kench, D.M. Russell, R. Yawger, and D. Nemazee. 1996. Analysis of central B cell tolerance in autoimmune-prone MRL/lpr mice bearing autoantibody transgenes. J. Immunol. 157:65–71.
- Roark, J.H., C.L. Kuntz, K.A. Nguyen, L. Mandik, M. Cattermole, and J. Erikson. 1995. B cell selection and allelic exclusion of an anti-DNA Ig transgene in MRL-lpr/lpr mice. *J. Immunol.* 154:4444–4455.
- 27. Kofler, R., R. Strohal, R.S. Balderas, M.E. Johnson, D.J. Noonan, M.A. Duchosal, F.J. Dixon, and A.N. Theo-filopoulos. 1988. Immunoglobulin k light chain variable region gene complex organization and immunoglobulin genes encoding anti-DNA autoantibodies in lupus mice. J. Clin. Invest. 82:852–860.
- Theofilopoulos, A.N., R. Kofler, P.A. Singer, and F.J. Dixon. 1989. Molecular genetics of murine lupus models. *Adv. Immunol.* 46:61–109.

- Bailey, N.C., K.N. Kasturi, K.T. Blackwell, F.W. Alt, and C.A. Bona. 1991. Complexity of the immunoglobulin light chain Vk1 gene family in the New Zealand black mouse. *Int. Immunol.* 3:751–760.
- 30. Lacour, M., and S. Izui. 1991. Lack of anti-DNA precursors in λ chain bearing B lymphocytes in (NZB × NZW) F1 mice. Evidence for the contribution of Vk genes to anti-DNA specificity. *Eur. J. Immunol.* 21:839–842.
- Radic, M.Z., M.A. Mascelli, J. Erikson, H. Shan, and M. Weigert. 1991. Ig H and L chain contributions to autoimmune specificities. *J. Immunol.* 146:176–182.
- 32. Retter, M.W., R.A. Eisenberg, P.L. Cohen, and S.H. Clarke. 1995. Sm and DNA binding by dual reactive B cells requires distinct VH, Vk and VH CDR3 structures. *J. Immu*nol. 155:2248–2257.
- 33. Lafer, E.M., J. Rauch, G. Andrzejewski, Jr., D. Mudd, B.C. Furie, B. Furie, and R.S. Schwartz. 1981. Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. J. Exp. Med. 153:897–909.
- 34. Lake, R.A., A. Morgan, B. Henderson, and N.A. Staines. 1985. A key role for fibronectin in the sequential binding of native dsDNA and monoclonal anti-DNA antibodies to components of the extracellular matrix: its possible significance in glomerulonephritis. *Immunology*. 54:389–395.
- Ohnishi, K., F.M. Ebling, B. Mitchell, R.R. Singh, B.H. Hahn, and B.P. Tsao. 1994. Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. *Int. Immunol.* 6:817–830.
- Bernstein, K.A., R. DiVarerio, and J.B. Lefkowith. 1995. Glomerular binding activity in MRL-lpr serum consists of antibodies that bind to a DNA/histone/type IV collagen complex. J. Immunol. 154:2424–2433.
- 37. Swanson, P.C., R.L. Yung, N.B. Blatt, M.A. Eagan, J.M. Norris, B.C. Richardson, K.J. Johnson, and G.D. Glick. 1996. Ligand recognition by murine anti-DNA autoantibodies. II. Genetic analysis and pathogenicity. *J. Clin. Invest.* 97: 1748–1760.
- Corbet, S., M. Milili, M. Fougereau, and C. Schiff. 1987. Two V-kappa germ-line genes related to the GAT idiotypic network (Ab1 and Ab3/Ab1') account for the major subfamilies of the mouse V-kappa-1 variability subgroup. J. Immunol. 138:932–939.
- Matsuda, T., and E.A. Kabat. 1989. Variable region cDNA sequences and antigen binding specificity of mouse monoclonal antibodies to isomaltosyl oligosaccharides coupled to proteins. J. Immunol. 142:863–870.
- Kabat, E.A., T.T. Wu, M. Reid-Miller, H.M. Perry, and K.S. Gottesman. 1987. Sequence of Proteins of Immunological Interest. U.S. Department of Health and Human Services Washington, DC.
- Ng, K.H., A. Lavigueur, L. Ricard, M. Boivrette, S. Ma-Clean, D. Cloutier, and D.M. Gibson. 1989. Characterization of allelic Vk-1 region genes in inbred strains of mice. *J. Immunol.* 143:638–648.